干扰素治疗慢性乙型肝炎的药物经济学研究

为了对干扰素治疗慢性乙型肝炎的疗效和费用进行药物经济学研究 ,选择有效病例 10 0例 ,治疗组 5 0例用干扰素 ,对照组 5 0例用拉米夫定。以 HBe Ag和 HBV-DNA作为抗病毒效果指标 ,以 ALT及临床症状体征作为疗效观察指标 ,以成本效果比作为药物经济学评价指标进行了分析。结果显示 ,两组药物均能有效治疗慢性乙肝。干扰素治疗组的近期抗病毒效果与对照组相比有显著差异 ,治疗组 HBe Ag转阴率优于对照组 ,干扰素治疗组的费用是对照组拉米夫定的 2倍以上

Studying Pharmacoeconomics of Interferon Cures the Chronic Hepatitis B

To assess the efficacy and cost of interferon in treatment of chronic hepatitis B. 100 patients were enrolled and they were divided into the active and the contol groups (n=100). The contol group (n=50) were treated with lamivudine.The active group(n=50)were trend with interferon. The antivirial response rate was expressed as HBeAg and HBV-DNA; the clinical responses were expressed as ALT, Clinical symptoms and physical signs; and the pharmacoeconomics was measured by cost effectiveness ratio. Significant differences existed between the two groups in short-term antivirial response in seroconversion for HBeAg. The average costs in interferon group are over two times of control group’s.